Notre Dame Patient Advocacy Initiative receives support from Dyne Therapeutics
September 20, 2022
September 20, 2022
NOTRE DAME, Indiana, Sept. 20 (TNSres) -- The University of Notre Dame issued the following news on Sept. 19, 2022:
Dyne Therapeutics, a leading muscle disease company focused on advancing innovative, life-transforming therapeutics for people living with genetically driven diseases, has made a commitment of $500,000 over five years in support of the University of Notre Dame's Patient Advocacy Initiative. In addition, Dyne has pledged a similar amount of in-kind support for the progr . . .
Dyne Therapeutics, a leading muscle disease company focused on advancing innovative, life-transforming therapeutics for people living with genetically driven diseases, has made a commitment of $500,000 over five years in support of the University of Notre Dame's Patient Advocacy Initiative. In addition, Dyne has pledged a similar amount of in-kind support for the progr . . .